Global Blood Stream Infection Testing Market Set for Strong Expansion Reaching $14.7 Billion by 2030 at 11.6% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Blood Stream Infection Testing Market By 2030 Starting From Its 2026 Size?
The blood stream infection testing market size has observed swift expansion in recent years. It is forecast to grow from $8.49 billion in 2025 to $9.5 billion in 2026, at a compound annual growth rate (CAGR) of 11.9%. The historical period’s growth can be attributed to the increasing incidence of bloodstream infections, rising hospital-acquired infection rates, the expansion of clinical microbiology laboratories, the adoption of automated diagnostic instruments, and growing awareness of sepsis management.
The market for blood stream infection testing is anticipated to experience significant expansion over the coming years. By 2030, this market is projected to reach a valuation of $14.71 billion, demonstrating a compound annual growth rate (CAGR) of 11.6%. This projected growth is driven by several factors, including a heightened need for swift diagnostic results, the increasing use of molecular diagnostics within healthcare facilities, the advancement of individualized infection management, rising investments in sophisticated laboratory infrastructure, and the greater incorporation of AI-powered diagnostic instruments. Key developments expected during this period involve the wider embrace of rapid molecular diagnostic tests, a surge in the deployment of automated blood culture platforms, the increasing incorporation of antimicrobial susceptibility analyses, the broadening of multiplex pathogen identification panels, and a stronger emphasis on identifying sepsis at an early stage.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20514&type=smp
What Drivers Are Shaping The Future Growth Of The Blood Stream Infection Testing Market?
A rising incidence of infectious diseases is projected to drive expansion in the blood stream infection testing market in the coming years. These conditions are characterized as ailments resulting from disease-causing microorganisms, including bacteria, viruses, fungi, or parasites. The rates of infectious diseases are escalating due to multiple contributors like heightened international travel, growing urbanization, shifts in climate, resistance to antibiotics, and insufficient vaccination. Within the context of infectious diseases, blood stream infection testing plays a crucial role in diagnosing and pinpointing the pathogens responsible for sepsis and other serious infections, thereby facilitating specific and efficient therapeutic approaches. As an illustration, data from October 2024 by the World Health Organization, an international public health body based in Switzerland, indicated that approximately 8.2 million individuals received a new tuberculosis diagnosis in 2023, representing an increase from about 7.5 million in 2022, establishing tuberculosis as the foremost fatal infectious disease. Consequently, the growing frequency of infectious diseases is propelling the blood stream infection testing market.
Which Segment Categories Define The Blood Stream Infection Testing Market?
The blood stream infection testing market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Sample Type: Whole Blood, Blood Culture
3) By Technology: Polymerase Chain Reaction (PCR), Mass Spectroscopy, In Situ Hybridization, Other Technologies
4) By End-User: Hospitals And Diagnostic Centers, Laboratory Service Providers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Instruments: Blood Culture Systems, Automated Microbial Identification Systems, Molecular Diagnostic Instruments
2) By Reagents And Consumables: Blood Culture Media, Antimicrobial Susceptibility Testing Reagents, Nucleic Acid Extraction Kits
3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Maintenance And Support Services
How Are Trends Transforming The Blood Stream Infection Testing Market Landscape?
Leading companies within the blood stream infection testing market are increasingly concentrating on integrating cutting-edge technologies, such as host-response diagnostics based on machine learning, to enhance rapid detection, improve clinical decision support, and foster potential advancements in patient management. Host-response diagnostics function by analyzing a patient’s immune system via gene expression signatures found in blood samples, employing artificial intelligence (AI)-derived algorithms to infer the presence, specific type, and likely severity of an infection in real time, thereby enabling clinicians to make faster and more accurate treatment decisions. For instance, in January 2025, Inflammatix Inc., a US-based molecular diagnostics company, obtained clearance from the US Food and Drug Administration for TriVerity. This machine-learning-based molecular blood test is designed to assist in the swift evaluation of patients with suspected acute infections or sepsis, featuring the measurement of 29 immune-related mRNAs and providing AI-generated scores indicating the likelihood of bacterial infection, viral infection, and the risk of severe illness, with results intended to be available in roughly 30 minutes. TriVerity supports clinical decision-making by reducing diagnostic uncertainty, aiding timely targeted therapy, and helping optimize hospital resource utilization when utilized alongside standard clinical evaluation and other laboratory findings.
Who Are The Top Companies Competing In The Blood Stream Infection Testing Market?
Major companies operating in the blood stream infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthcare Private Limited, Becton Dickinson and Company (BD), Grifols S.A., Hologic Inc., BIOMÉRIEUX SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., DiaSorin S.p.A., Seegene Inc., Cepheid, Meridian Bioscience Inc., Biocartis NV, T2 Biosystems Inc., Molzym GmbH & Co. KG, Curetis GmbH, Accelerate Diagnostics Inc., OpGen Inc.
Read the full blood stream infection testing market report here:
Which Geographic Regions Are Influencing Demand In The Blood Stream Infection Testing Market?
North America was the largest region in the blood stream infection testing market in 2025. The regions covered in the blood stream infection testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Blood Stream Infection Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20514&type=smp
Browse Through More Reports Similar to the Global Blood Stream Infection Testing Market 2026, By The Business Research Company
Infection Control Supplies Global Market Report
https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report
Urinary Tract Infection Treatment Global Market Report
Preoperative Infection Prevention And Wound Cleansing Devices Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
